NMIBC – Medxy AI

Atezolizumab and BCG Combination Fails to Improve Event-Free Survival in High-Risk NMIBC: Results from the ALBAN Phase III Trial

By MedXY 01/14/2026

The Phase III ALBAN trial found that adding atezolizumab to BCG therapy did not improve event-free survival in BCG-naive high-risk non-muscle-invasive bladder cancer, highlighting the complexity of immune checkpoint inhibitor synergy in this setting.

news Oncology Urology

The Evolving Paradigm in High-Risk NMIBC: Critical Synthesis of Checkpoint Inhibitors and BCG Combination Therapy

By MedXY 01/10/2026

A comprehensive meta-analysis of the POTOMAC, CREST, and ALBAN trials reveals that adding PD-(L)1 inhibitors to BCG improves event-free survival in high-risk NMIBC. However, increased toxicity and agent-specific variations in efficacy suggest a need for cautious, individualized clinical adoption.

news Oncology Urology

Audit and Feedback in NMIBC Surgery: Improved Documentation Does Not Translate to Better Clinical Outcomes

By MedXY 01/10/2026

A global cluster randomized trial (RESECT) demonstrates that while audit and feedback improve surgical documentation in non-muscle-invasive bladder cancer, they fail to enhance detrusor muscle sampling, adjuvant chemotherapy use, or early recurrence rates.

Clinical Updates news Oncology

Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial

By MedXY 01/09/2026

The phase III ALBAN trial found no benefit in adding atezolizumab to BCG for BCG-naive high-risk NMIBC, emphasizing that immunotherapy benefits in this space are likely agent-specific and necessitate better biomarker-driven selection.

Clinical Updates news Oncology Specialties

Oral Metformin in Non-Muscle-Invasive Bladder Cancer: Insights from a Phase II Marker Lesion Study

By MedXY 09/15/2025

A phase II trial assessing oral metformin for low-grade non-muscle-invasive bladder cancer (NMIBC) found minimal antitumor activity and no significant mechanistic changes, challenging metformin’s role as an intravesical therapeutic agent in this context.